MarketCap
Facebook
X
Telegram
EyePoint Pharmaceuticals Balance Sheet 2025-2009 | EYPT
Brief balance sheet overview of EyePoint Pharmaceuticals
Balance sheet changes are traced across five available annual reports between 2021 and 2025.
Assets increased from $263.4 million to $364 million, or +38.2%; CAGR of about 8.4% indicates steady balance sheet expansion.
Assets outpaced liabilities, +38.2% versus -26.7%. Dependence on external funding declined.
Internal capital represents 84.1% of the balance sheet, previously 70%. This is a strong capital position.
Cash exceeds interest-bearing debt, producing net debt of -$79 million. The balance sheet therefore carries a net cash position.
Cash represents 28% of assets versus 67.8% initially, showing how the immediate liquidity reserve changed.
Retained earnings remain negative at -$1.1 billion. This may reflect past losses or substantial shareholder distributions, so earnings and buybacks provide important context.
What the balance sheet shows
EyePoint Pharmaceuticals shows a high-quality balance sheet profile, with adequate internal capital and room for maneuver.
Annual Balance Sheet EyePoint Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-79 M | -76.6 M | -276 M | -65.8 M | -141 M | 1.4 M | 28.4 M | -21.5 M | -16.9 M | -15.3 M | -19.1 M | -15.3 M | -6.9 M | -4.62 M | -12.9 M | - | - |
Long Term Debt |
20.8 M | 21.9 M | 4.91 M | 29.3 M | 36.6 M | 38 M | 47.2 M | 17.3 M | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
2.02 M | 1.25 M | 563 K | 543 K | 645 K | 568 K | 481 K | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 58.3 M | 53.1 M | 38.3 M | 51 K | 5.64 M | 5.65 M | 5.62 M | 5.25 M | 3.78 M | 4.65 M | - | - |
Total Current Liabilities |
37 M | 49 M | 63.3 M | 34.5 M | 23.7 M | 14.9 M | 11.5 M | 21.5 M | 5.29 M | 5.09 M | 3.35 M | 2.13 M | 3.3 M | 3.18 M | - | - | - |
Total Liabilities |
57.9 M | 82 M | 88.9 M | 84 M | 79 M | 73.2 M | 64.6 M | 60 M | 5.34 M | 10.7 M | 9 M | 7.75 M | 8.55 M | 6.96 M | 9.68 M | - | - |
Deferred Revenue |
- | 17.8 M | 38.6 M | 1.2 M | 1.07 M | 945 K | 15 K | - | 50 K | 147 K | 33 K | 138 K | 738 K | 2.18 M | 3.21 M | - | - |
Retained Earnings |
-1.1 B | -873 M | -742 M | -671 M | -569 M | -511 M | -465 M | -364 M | -311 M | -292 M | -271 M | -277 M | -264 M | -252 M | -227 M | - | - |
Total Assets |
364 M | 418 M | 355 M | 180 M | 263 M | 91.7 M | 73 M | 71.7 M | 18.7 M | 31.6 M | 32.4 M | 22.7 M | 16.2 M | 20.6 M | 47.1 M | - | - |
Cash and Cash Equivalents |
102 M | 99.7 M | 281 M | 95.6 M | 179 M | 44.9 M | 22.2 M | 45.3 M | 16.9 M | 15.3 M | 19.1 M | 15.3 M | 6.9 M | 4.62 M | 12.9 M | 15.5 M | 6.9 M |
Book Value |
306 M | 337 M | 266 M | 96.4 M | 184 M | 18.5 M | 8.33 M | 11.7 M | 13.3 M | 20.9 M | 23.4 M | 14.9 M | 7.7 M | 13.6 M | 37.4 M | - | - |
Total Shareholders Equity |
306 M | 337 M | 266 M | 96.4 M | 184 M | 18.5 M | 8.33 M | 37.6 M | 13.3 M | 20.9 M | 23.4 M | 14.9 M | 7.7 M | 13.6 M | 37.4 M | 33 M | 23.5 M |
All numbers in USD currency
Quarterly Balance Sheet EyePoint Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
20.2 M | 21.3 M | 21.8 M | 22.3 M | 21.9 M | 21.9 M | 22.2 M | - | 4.91 M | - | - | 29.4 M | 29.3 M | 29.3 M | - | 29.1 M | 36.6 M | 36.4 M | 36.2 M | 38.1 M | 38 M | 38 M | 38 M | 38 M | 47.2 M | 47.2 M | 47.2 M | 47.2 M | 17.6 M | 17.6 M | 17.6 M | 17.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
57.7 M | 51.5 M | 55.1 M | 64.2 M | 82 M | 82.2 M | 95.9 M | - | 88.9 M | 101 M | 118 M | 76.2 M | 84 M | 84.1 M | - | 77.7 M | 79 M | 75.5 M | 72 M | 71.4 M | 73.2 M | 73.2 M | 73.2 M | 73.2 M | 64.6 M | 64.6 M | 64.6 M | 64.6 M | 40.5 M | 40.5 M | 40.5 M | 40.5 M | 4.29 M | 4.33 M | 5.34 M | 5.34 M | 4.98 M | 10.5 M | 10.7 M | 10.7 M | 9.53 M | 8.64 M | 9 M | 9 M | 7.9 M | 7.94 M | 7.75 M | 7.75 M | 8.22 M | 8.5 M | 8.55 M | 8.55 M | 7.23 M | 7.18 M | 6.96 M | 6.96 M | 7.16 M | 7.91 M | 9.68 M | 9.68 M |
Deferred Revenue |
- | - | - | 5.12 M | 17.8 M | 26 M | 33.3 M | - | 38.6 M | 39.8 M | 42.1 M | 1.24 M | 1.2 M | 1.17 M | - | 1.1 M | 1.07 M | 1.04 M | 1.01 M | 973 K | 945 K | 945 K | 945 K | 945 K | 15 K | 15 K | 15 K | 15 K | 30 K | 30 K | 30 K | 30 K | 505 K | 10 K | 50 K | 50 K | 136 K | 139 K | 147 K | 147 K | 28 K | 33 K | 33 K | 33 K | 69 K | 104 K | 138 K | 138 K | 771 K | 688 K | 738 K | 738 K | 784 K | 2.4 M | 2.18 M | 2.18 M | 1.72 M | 2.51 M | 3.21 M | 3.21 M |
Retained Earnings |
-1.19 B | -1.04 B | -978 M | -918 M | -873 M | -832 M | -802 M | - | -742 M | -728 M | -715 M | -693 M | -671 M | -628 M | - | -590 M | -569 M | -550 M | -533 M | -523 M | -511 M | -511 M | -511 M | -511 M | -465 M | -465 M | -465 M | -465 M | -408 M | -408 M | -408 M | -408 M | -323 M | -317 M | -311 M | -311 M | -299 M | -299 M | -292 M | -292 M | -281 M | -276 M | -271 M | -271 M | -261 M | -256 M | -277 M | -277 M | -271 M | -267 M | -264 M | -264 M | -257 M | -254 M | -252 M | -252 M | -247 M | -229 M | -227 M | -227 M |
Total Assets |
288 M | 252 M | 301 M | 363 M | 418 M | 301 M | 324 M | - | 355 M | 160 M | 176 M | 155 M | 180 M | 220 M | - | 245 M | 263 M | 168 M | 179 M | 187 M | 91.7 M | 91.7 M | 91.7 M | 91.7 M | 73 M | 73 M | 73 M | 73 M | 78.2 M | 78.2 M | 78.2 M | 78.2 M | 14.2 M | 13.3 M | 18.7 M | 18.7 M | 19.7 M | 24.9 M | 31.6 M | 31.6 M | 24 M | 27.5 M | 32.4 M | 32.4 M | 40.2 M | 43.7 M | 22.7 M | 22.7 M | 20.8 M | 22.7 M | 16.2 M | 16.2 M | 21 M | 23.3 M | 20.6 M | 20.6 M | 24.9 M | 43.1 M | 47.1 M | 47.1 M |
Cash and Cash Equivalents |
77.7 M | 74.6 M | 71.1 M | 85.2 M | 99.7 M | 79.8 M | 90.8 M | 271 M | 281 M | 133 M | 140 M | 106 M | 95.6 M | 75.4 M | 82.1 M | 102 M | 179 M | 120 M | 128 M | 139 M | 44.9 M | 44.9 M | 44.9 M | 44.9 M | 22.2 M | 22.2 M | 22.2 M | 22.2 M | 45.3 M | 45.3 M | 45.3 M | 45.3 M | 12.9 M | 11.8 M | 16.9 M | 16.9 M | 11.7 M | 14.3 M | 11.7 M | 14.3 M | 11.2 M | 14.1 M | 11.2 M | 14.1 M | 29.8 M | 11.4 M | 29.8 M | 11.4 M | 15.2 M | 14.5 M | 15.2 M | 14.5 M | 9.41 M | 8.39 M | 9.41 M | 8.39 M | 8.41 M | 9.81 M | 8.41 M | 9.81 M |
Book Value |
230 M | 200 M | 246 M | 298 M | 337 M | 219 M | 228 M | - | 266 M | 58.6 M | 57.3 M | 78.4 M | 96.4 M | 136 M | - | 167 M | 184 M | 92.7 M | 107 M | 116 M | 18.5 M | 18.5 M | 18.5 M | 18.5 M | 8.33 M | 8.33 M | 8.33 M | 8.33 M | 37.6 M | 37.6 M | 37.6 M | 37.6 M | 9.9 M | 9 M | 13.3 M | 13.3 M | 14.8 M | 14.4 M | 20.9 M | 20.9 M | 14.4 M | 18.8 M | 23.4 M | 23.4 M | 32.3 M | 35.8 M | 14.9 M | 14.9 M | 12.6 M | 14.2 M | 7.7 M | 7.7 M | 13.8 M | 16.2 M | 13.6 M | 13.6 M | 17.8 M | 35.2 M | 37.4 M | 37.4 M |
Total Shareholders Equity |
230 M | 200 M | 246 M | 298 M | 337 M | 219 M | 228 M | 250 M | 266 M | 58.6 M | 57.3 M | 78.4 M | 96.4 M | 136 M | 151 M | 167 M | 184 M | 92.7 M | 107 M | 116 M | 18.5 M | 18.5 M | 18.5 M | 18.5 M | 8.33 M | 8.33 M | 8.33 M | 8.33 M | 37.6 M | 37.6 M | 37.6 M | 37.6 M | 9.9 M | 9 M | 9.9 M | 9 M | 14.8 M | 14.3 M | 14.8 M | 14.4 M | 14.4 M | 18.8 M | 14.4 M | 18.8 M | 32.3 M | 35.8 M | 32.3 M | 14.9 M | 12.6 M | 14.2 M | 7.7 M | 7.7 M | 13.8 M | 16.2 M | 13.6 M | 13.6 M | 17.8 M | 35.2 M | 37.4 M | 37.4 M |
All numbers in USD currency
Balance Sheet is a fundamental financial report of EyePoint Pharmaceuticals, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Canada
China
USA
France
Singapore
Britain
Germany
Israel
Russia
Belgium
Niderland
Irlanda
